Risperidone ISM 100 mg

DRUG3 trials

Sponsors

Rovi Pharmaceuticals Laboratories

Conditions

Acute SchizophreniaSchizoaffective DisorderSchizophrenia

Phase 1

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

CompletedNCT01788774

Rovi Pharmaceuticals LaboratoriesSchizoaffective Disorder, Schizophrenia

Start: 2013-04-30End: 2014-02-28Updated: 2023-10-23

Phase 3

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

CompletedNCT03160521

Rovi Pharmaceuticals LaboratoriesAcute Schizophrenia

Start: 2017-06-02End: 2018-12-17Updated: 2022-02-22

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

CompletedNCT03870880

Rovi Pharmaceuticals LaboratoriesSchizophrenia

Start: 2017-08-25End: 2020-01-08Updated: 2022-03-25

Related Papers

No sex-related differences in PANSS score reductions in adult patients with acutely exacerbated schizophrenia treated with Risperidone ISM

European Psychiatry2025-04-01

No sex-related differences in CGI-S score reductions in adult patients with acutely exacerbated schizophrenia treated with Risperidone ISM

European Psychiatry2025-04-01

Sex-related differences in long-term tolerability of Risperidone ISM treatment in adult patients with schizophrenia

European Psychiatry2025-04-01

Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

Schizophrenia2020-11-2535 citations